$SCYYF

2022 Q4 Form 10-Q Financial Statement

#000165495422015016 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $98.92K $166.0K $190.3K
YoY Change -48.01% -37.81% -70.73%
% of Gross Profit
Research & Development $7.500K $22.92K $14.58K
YoY Change -48.56% -31.5% -51.4%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $420.00
YoY Change -100.0% -100.0%
% of Gross Profit
Operating Expenses $106.4K -$189.0K $205.3K
YoY Change -48.16% -162.81% -70.25%
Operating Profit
YoY Change
Interest Expense $334.8K $259.7K -$9.850K
YoY Change -3498.88% 1072.81% -50.75%
% of Operating Profit
Other Income/Expense, Net $0.00 $0.00
YoY Change
Pretax Income $228.4K $70.70K -$215.1K
YoY Change -206.16% -125.37% -69.7%
Income Tax
% Of Pretax Income
Net Earnings $228.4K $70.70K -$215.1K
YoY Change -206.16% -125.37% -69.55%
Net Earnings / Revenue
Basic Earnings Per Share $0.00
Diluted Earnings Per Share $0.00 $198.70 -$679.80
COMMON SHARES
Basic Shares Outstanding 355.9M shares 355.9M shares 316.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.853M $1.972M $93.89K
YoY Change 1873.28% 2966.72% -44.77%
Cash & Equivalents $1.853M $1.972M $93.89K
Short-Term Investments
Other Short-Term Assets $33.54K $10.06K $35.04K
YoY Change -4.28% -44.94% -12.4%
Inventory
Prepaid Expenses $33.54K $10.06K $35.04K
Receivables
Other Receivables
Total Short-Term Assets $1.886M $1.982M $128.9K
YoY Change 1362.94% 2300.33% -39.39%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00 $2.932K
YoY Change -100.0% -100.0% -37.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.70K $9.800K $11.44K
YoY Change -6.47% -14.34% 14.4%
Other Assets
YoY Change
Total Long-Term Assets $714.8K $713.9K $718.4K
YoY Change -0.51% -0.7% -0.24%
TOTAL ASSETS
Total Short-Term Assets $1.886M $1.982M $128.9K
Total Long-Term Assets $714.8K $713.9K $718.4K
Total Assets $2.601M $2.696M $847.4K
YoY Change 206.95% 236.38% -9.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $312.8K $175.9K $1.160M
YoY Change -73.02% -83.13% 65.67%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.508M $1.860M $1.728M
YoY Change -12.73% 20.96% 50.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.508M $1.860M $1.728M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.508M $1.860M $1.728M
YoY Change -12.73% 20.96% 49.66%
SHAREHOLDERS EQUITY
Retained Earnings -$115.0M -$115.2M -$115.8M
YoY Change -0.73% -0.35% 1.37%
Common Stock $111.1M $111.2M $110.1M
YoY Change 0.9% 1.03% 0.48%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.264M $1.264M $1.264M
YoY Change 0.0% 0.0% 0.0%
Treasury Stock Shares 1.033M shares 1.033M shares 1.033M shares
Shareholders Equity $1.093M $836.2K -$880.3K
YoY Change
Total Liabilities & Shareholders Equity $2.601M $2.696M $847.4K
YoY Change 206.95% 236.38% -9.17%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income $228.4K $70.70K -$215.1K
YoY Change -206.16% -125.37% -69.55%
Depreciation, Depletion And Amortization $0.00 $0.00 $420.00
YoY Change -100.0% -100.0%
Cash From Operating Activities -$99.30K -$342.1K -$41.16K
YoY Change 141.25% 259.85% -62.58%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.89K 0.000 70.76K
YoY Change -128.11% -49.46%
NET CHANGE
Cash From Operating Activities -99.30K -342.1K -41.16K
Cash From Investing Activities
Cash From Financing Activities -19.89K 0.000 70.76K
Net Change In Cash -119.2K -342.1K 29.60K
YoY Change -502.67% 259.85% -1.33%
FREE CASH FLOW
Cash From Operating Activities -$99.30K -$342.1K -$41.16K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
317157595 shares
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1033333 shares
CY2021Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
1033333 shares
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
419 usd
us-gaap Legal Fees
LegalFees
18363 usd
us-gaap Legal Fees
LegalFees
105122 usd
CY2022Q3 scy Exploration Recovery
ExplorationRecovery
22915 usd
scy Exploration Recovery
ExplorationRecovery
-8455 usd
CY2022Q3 scy General And Administrative Expenses
GeneralAndAdministrativeExpenses
29822 usd
CY2021Q3 scy General And Administrative Expenses
GeneralAndAdministrativeExpenses
90683 usd
scy General And Administrative Expenses
GeneralAndAdministrativeExpenses
160933 usd
scy General And Administrative Expenses
GeneralAndAdministrativeExpenses
181740 usd
us-gaap General Insurance Expense
GeneralInsuranceExpense
23052 usd
us-gaap General Insurance Expense
GeneralInsuranceExpense
27778 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
23939 usd
CY2021Q3 us-gaap Professional Fees
ProfessionalFees
5185 usd
us-gaap Professional Fees
ProfessionalFees
87261 usd
us-gaap Professional Fees
ProfessionalFees
53194 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
42129 usd
CY2021Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
116112 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
180256 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
350287 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
33767 usd
us-gaap Net Income Loss
NetIncomeLoss
-1351921 usd
scy Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
scy Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
316075086 shares
CY2021Q4 scy Reclamation Bond Non Current Asset
ReclamationBondNonCurrentAsset
11444 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2932 usd
CY2021Q4 us-gaap Mineral Rights
MineralRights
704053 usd
CY2021Q4 us-gaap Assets
Assets
847365 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2932 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1309 usd
CY2022Q3 us-gaap Legal Fees
LegalFees
1363 usd
CY2021Q3 us-gaap Legal Fees
LegalFees
45500 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001408146
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
317157595 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
355860813 shares
CY2021 us-gaap Acquisition Costs
AcquisitionCosts
704053 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
37803218 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29065000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34610000 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
35015000 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.19
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.14
scy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0 pure
scy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2021Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1264194 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-54416
dei Entity Registrant Name
EntityRegistrantName
SCANDIUM INTERNATIONAL MINING CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
Z4
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1009717
dei Entity Address Address Line1
EntityAddressAddressLine1
1390 Ione Pass Trail
dei Entity Address City Or Town
EntityAddressCityOrTown
Reno
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89523
dei City Area Code
CityAreaCode
775
dei Local Phone Number
LocalPhoneNumber
355-9500
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
355860813 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
355860813 shares
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0 usd
CY2021Q3 scy Exploration Recovery
ExplorationRecovery
33458 usd
scy Exploration Recovery
ExplorationRecovery
55873 usd
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
61222 usd
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
149669 usd
us-gaap Share Based Compensation
ShareBasedCompensation
610385 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
-188955 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
-300848 usd
us-gaap Operating Expenses
OperatingExpenses
-614011 usd
us-gaap Operating Expenses
OperatingExpenses
-1385688 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
44862 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
22144 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
43139 usd
CY2022Q3 scy Accruals Reversal
AccrualsReversal
0 usd
CY2021Q3 scy Accruals Reversal
AccrualsReversal
0 usd
scy Accruals Reversal
AccrualsReversal
1032044 usd
CY2022Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
214794 usd
CY2021Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
161053 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
70701 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-278704 usd
us-gaap Net Income Loss
NetIncomeLoss
622225 usd
CY2022Q3 scy Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
0.00
CY2021Q3 scy Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
-0.00
scy Earning Per Share Basic And Diluted
EarningPerShareBasicAndDiluted
0.00
CY2022Q3 scy Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
355860813 shares
CY2021Q3 scy Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
316272595 shares
scy Weighted Average Number Of Shares Outstanding Basic And Diluted
WeightedAverageNumberOfSharesOutstandingBasicAndDiluted
345147171 shares
scy Profits Loss
ProfitsLoss
622225 usd
scy Profits Loss
ProfitsLoss
-1351921 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2932 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1309 usd
scy Stock Based Compensation
StockBasedCompensation
149669 usd
scy Stock Based Compensation
StockBasedCompensation
610385 usd
scy Accrual Reversal
AccrualReversal
1032044 usd
scy Accrual Reversal
AccrualReversal
0 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
161053 usd
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
99292 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
0 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-24987 usd
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-24161 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-355843 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
383019 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-848419 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-333047 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2647852 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Stock Issued1
StockIssued1
28418 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
106989 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
227064 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2726423 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
227064 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1878004 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-105983 usd
CY2021Q4 us-gaap Cash
Cash
93894 usd
CY2020Q4 us-gaap Cash
Cash
170284 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1971898 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
64301 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-221517 usd
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
227064 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-312137 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-306590 usd
CY2021Q2 scy Stock Based Compensation
StockBasedCompensation
610385 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-761080 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-457285 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-278704 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-735989 usd
CY2021Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
70751 usd
CY2021Q4 us-gaap Net Income Loss
NetIncomeLoss
-215111 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-880349 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
522946 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-357403 usd
CY2022Q2 scy Stock Based Compensation
StockBasedCompensation
88447 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
106989 usd
CY2022Q2 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
2619434 usd
CY2022Q2 scy Derivative Liability
DerivativeLiability
-1781779 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>1.</strong> <strong>NATURE AND CONTINUANCE OF OPERATIONS</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">Scandium International is a specialty metals and alloys company focusing on scandium and other specialty metals.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company was incorporated under the laws of the Province of British Columbia, Canada in 2006. The Company currently trades on the Toronto Stock Exchange under the symbol “SCY”.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company’s focus is on the exploration and evaluation of its specialty metals assets, specifically the Nyngan scandium deposit located in New South Wales, Australia, The Company is an exploration stage company and anticipates incurring significant additional expenditures prior to production at any and all of its properties.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">These condensed consolidated financial statements have been prepared on a going concern basis that contemplates the realization of assets and discharge of liabilities at their carrying values in the normal course of business for the foreseeable future. These financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company currently earns no operating revenues and will require additional capital in order to advance the Nyngan property. The Company’s ability to continue as a going concern is uncertain and is dependent upon the generation of profits from mineral properties, obtaining additional financing and maintaining continued support from its shareholders and creditors. These are material uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern. In the event that additional financial support is not received, or operating profits are not generated, the carrying values of the Company’s assets may be adversely affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">In March 2020, the World Health Organization declared coronavirus COVID-19 a global pandemic. This contagious disease outbreak, which has continued to spread, and related adverse public health developments, have adversely affected workforces, economies, and financial markets globally, leading to an economic downturn. It is not possible for the Company to predict the duration or magnitude of the adverse results of the outbreak and its effects on the Company’s business or ability to raise funds.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The preparation of unaudited interim condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuations, asset impairment, stock-based compensation, derivative liabilities and loss contingencies. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between estimates and the actual results, future results of operations will be affected.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">The Company considers itself to be an exploration stage company and will consider the transition to development stage after it receives funding to begin mine construction, and board approval.</p>
us-gaap Debt Instrument Term
DebtInstrumentTerm
P12Y
us-gaap Short Term Lease Cost
ShortTermLeaseCost
15669 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
22445 usd
CY2021Q4 scy Weighted Average Exercise Price Of Warrants Outstanding
WeightedAverageExercisePriceOfWarrantsOutstanding
0
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1971898 usd
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1519787 usd
us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
37803218 shares
scy Weighted Average Exercise Price Granted Of Warrants
WeightedAverageExercisePriceGrantedOfWarrants
0.1075
scy Expiration Date
ExpirationDate
May 20 - June 14, 2027
CY2022Q3 scy Weighted Average Exercise Price Of Warrants Outstanding
WeightedAverageExercisePriceOfWarrantsOutstanding
0.1075
us-gaap Acquisition Costs
AcquisitionCosts
704053 usd
scy Royalty Percentage On Gross Mineral Sales
RoyaltyPercentageOnGrossMineralSales
0.007 pure
scy Net Profits Interest Royalty Percentage
NetProfitsInterestRoyaltyPercentage
0.015 pure
scy Revenue Royalty Payable Percentage
RevenueRoyaltyPayablePercentage
0.002 pure
scy Revenue Royalty Is Payable
RevenueRoyaltyIsPayable
370000 usd
CY2022Q3 us-gaap Derivative Liability Notional Amount
DerivativeLiabilityNotionalAmount
161053 usd
CY2022Q3 us-gaap Derivative Assets
DerivativeAssets
1519787 usd
CY2022Q3 scy Accruals To Related Parties
AccrualsToRelatedParties
669733 usd
scy Stock Based Compensation For Stock Options
StockBasedCompensationForStockOptions
136540 usd
scy Stock Based Compensation For Stock Options
StockBasedCompensationForStockOptions
441277 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
17000 usd
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
76500 usd
CY2022Q3 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
175854 usd
CY2021Q4 us-gaap Due To Officers Or Stockholders Current And Noncurrent
DueToOfficersOrStockholdersCurrentAndNoncurrent
1159713 usd
CY2022Q3 scy Fair Value Derivative Liability
FairValueDerivativeLiability
1781779 usd
CY2022Q3 scy Common Shares
CommonShares
106989 usd
scy Weighted Average Exercise Price Of Stock
WeightedAverageExercisePriceOfStock
0.15
CY2021Q3 scy Common Shares
CommonShares
227064 usd
us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.1075
CY2022Q2 us-gaap Warrant Exercise Price Increase
WarrantExercisePriceIncrease
0.1075
us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.085
CY2022Q2 us-gaap Stock Option Exercise Price Increase
StockOptionExercisePriceIncrease
0.09
scy Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P4Y8M12D
CY2022Q2 scy Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm
P5Y
scy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1
0.8989 pure
CY2022Q2 scy Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate1
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1
0.8569 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0275 pure
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0273 pure
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
35100000 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.17
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
6175000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.18
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
3125000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.12
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.16
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34615000 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.18
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
5700000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.09
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
4500000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
0.37
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34915000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.14
scy Number Currently Exercisable
NumberCurrentlyExercisable
30640000 shares
scy Number Currently Exercisable Price
NumberCurrentlyExercisablePrice
0.15
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
34915000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
30640000 shares
scy Schedule Of Stock Based Compensation
ScheduleOfStockBasedCompensation
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2022</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">2021</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" colspan="2" style="width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.79</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.32</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Expected life</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td colspan="2"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;">5 years</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Volatility</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">85.82</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">87.19</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Forfeiture rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Dividend rate</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">N/A</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
scy Risk Free Interest Rate
RiskFreeInterestRate
0.0279 pure
scy Risk Free Interest Rate
RiskFreeInterestRate
0.0032 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8582 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8719 pure
CY2022Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
1033333 shares
CY2022Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1264194 usd
scy Writeoff Of Accrualstextblock
WriteoffOfAccrualstextblock
<p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>9.</strong> <strong>ACCRUALS REVERSAL</strong> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;">During the nine-month period ended September 30, 2022, the Company recognized a recovery on historical accruals it has recorded totaling $669,733 to related parties (Note 5) and $362,311 to former contractors and consultants.</p>
CY2022Q3 scy Accruals To Related Parties
AccrualsToRelatedParties
669733 usd

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001654954-22-015016-index-headers.html Edgar Link pending
0001654954-22-015016-index.html Edgar Link pending
0001654954-22-015016.txt Edgar Link pending
0001654954-22-015016-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
scy-20220930.xsd Edgar Link pending
scy_10q.htm Edgar Link pending
scy_10qimg2.jpg Edgar Link pending
scy_10qimg21.jpg Edgar Link pending
scy_10qimg3.jpg Edgar Link pending
scy_ex311.htm Edgar Link pending
scy_ex312.htm Edgar Link pending
scy_ex321.htm Edgar Link pending
scy_ex322.htm Edgar Link pending
Show.js Edgar Link pending
scy-20220930_cal.xml Edgar Link unprocessable
scy-20220930_def.xml Edgar Link unprocessable
scy-20220930_lab.xml Edgar Link unprocessable
scy-20220930_pre.xml Edgar Link unprocessable
scy_10q_htm.xml Edgar Link completed